J&J/Curis
This article was originally published in The Gray Sheet
Executive Summary
Bone morphogenic protein technology license to Johnson & Johnson/Ortho Biotech Products includes a $3.5 mil. up-front payment to Curis, plus milestones and royalties. The pact encompasses BMP compounds to be further developed as therapeutics for systemic complications of chronic kidney disease; the deal excludes musculoskeletal repair. Curis will receive $30 mil. upon FDA approval of a kidney disease product...